TORL secures $158m for oncology pipeline development

Clinical-stage biotechnology company TORL BioTherapeutics has announced the closure of an oversubscribed $158m Series B-2 financing round.

Related Keywords

Mark Alles ,Bristol Myers Squibb ,Perceptive Xontogeny Venture Fund ,Deep Track Capital ,Perceptive Advisors ,Goldman Sachs Alternatives ,Moore Strategic Ventures ,Vertex Ventures ,Blue Owl Healthcare Opportunities ,Avidity Partners ,